Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Coenzyme Q10 in dilated cardiomyopathy.

U Manzoli1, E Rossi, G P Littarru

  • 1Institute of Cardiology, Catholic University, Rome, Italy.

International Journal of Tissue Reactions
|January 1, 1990
PubMed
Summary

Coenzyme Q10 (CoQ10) supplementation improved symptoms and heart function in dilated cardiomyopathy patients. This suggests CoQ10 deficiency is reversible and supplementation aids heart failure treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multitarget drugs of plants origin acting on Alzheimer's disease.

Current medicinal chemistry·2013
Same author

From traditional European medicine to discovery of new drug candidates for the treatment of dementia and Alzheimer's disease: acetylcholinesterase inhibitors.

Current medicinal chemistry·2012
Same author

Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy.

Herz·2012
Same author

Rehabilitation of traumatic brain injury in Italy: a multi-centred study.

Brain injury·2011
Same author

Atrial biopsy evidence of Fabry disease causing lone atrial fibrillation.

Heart (British Cardiac Society)·2010
Same author

Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome.

Human psychopharmacology·2010

Area of Science:

  • Cardiology
  • Biochemistry
  • Pharmacology

Background:

  • Dilated cardiomyopathy (DCM) is associated with reduced myocardial coenzyme Q10 (CoQ10) levels.
  • CoQ10 deficiency may contribute to the pathophysiology of DCM.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of oral CoQ10 in patients with DCM.
  • To assess the impact of CoQ10 on clinical symptoms, cardiac function, and CoQ10 levels in DCM patients.

Main Methods:

  • Thirty DCM patients received oral CoQ10 (100 mg/day) for two months.
  • Clinical (NYHA class) and echocardiographic (ejection fraction, ventricular volumes) assessments were performed before and after treatment.
  • Plasma and myocardial CoQ10 levels were measured.

Related Experiment Videos

Main Results:

  • 47% of patients showed symptom regression and improved NYHA class.
  • Ejection fraction significantly increased (0.31 to 0.37, p<0.001).
  • Plasma CoQ10 levels increased significantly (p<0.0001), with 95% of patients showing improvement.

Conclusions:

  • CoQ10 deficiency in DCM appears reversible with oral supplementation.
  • Therapeutic response correlates with baseline plasma and myocardial CoQ10 levels.
  • CoQ10 may be a valuable adjunct therapy for chronic heart failure in DCM.